These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23259660)

  • 1. Latin American women's experiences with medical abortion in settings where abortion is legally restricted.
    Zamberlin N; Romero M; Ramos S
    Reprod Health; 2012 Dec; 9(1):34. PubMed ID: 23259660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women's abortion seeking behavior under restrictive abortion laws in Mexico.
    Juarez F; Bankole A; Palma JL
    PLoS One; 2019; 14(12):e0226522. PubMed ID: 31881041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe abortion information hotlines: An effective strategy for increasing women's access to safe abortions in Latin America.
    Drovetta RI
    Reprod Health Matters; 2015 May; 23(45):47-57. PubMed ID: 26278832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Women's experiences with the use of medical abortion in a legally restricted context: the case of Argentina.
    Ramos S; Romero M; Aizenberg L
    Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):4-15. PubMed ID: 25702064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women's voices and medical abortions: A review of the literature.
    Alam B; Kaler A; Mumtaz Z
    Eur J Obstet Gynecol Reprod Biol; 2020 Jun; 249():21-31. PubMed ID: 32348948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misoprostol alone for early medical abortion in a Latin American clinic setting.
    Billings DL
    Reprod Health Matters; 2004 Nov; 12(24 Suppl):57-64. PubMed ID: 15938158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women's experiences.
    Fielding SL; Edmunds E; Schaff EA
    Perspect Sex Reprod Health; 2002; 34(1):34-40. PubMed ID: 11990637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "Abortion Pill" Misoprostol in Brazil: Women's Empowerment in a Conservative and Repressive Political Environment.
    Löwy I; Dias Villela Corrêa MC
    Am J Public Health; 2020 May; 110(5):677-684. PubMed ID: 32191521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical methods for first trimester abortion.
    Kulier R; Gülmezoglu AM; Hofmeyr GJ; Cheng LN; Campana A
    Cochrane Database Syst Rev; 2004; (2):CD002855. PubMed ID: 15106180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical methods for first trimester abortion.
    Kulier R; Gülmezoglu AM; Hofmeyr GJ; Cheng LN; Campana A
    Cochrane Database Syst Rev; 2004; (1):CD002855. PubMed ID: 14973995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How, when and where? A systematic review on abortion decision making in legally restricted settings in sub-Saharan Africa, Latin America, and the Caribbean.
    Hinson L; Bhatti AM; Sebany M; Bell SO; Steinhaus M; Twose C; Izugbara C
    BMC Womens Health; 2022 Oct; 22(1):415. PubMed ID: 36217197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion.
    Winikoff B; Sivin I; Coyaji KJ; Cabezas E; Xiao B; Gu S; Du MK; Krishna UR; Eschen A; Ellertson C
    Am J Obstet Gynecol; 1997 Feb; 176(2):431-7. PubMed ID: 9065194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women's perspectives on medical abortion in Mexico, Colombia, Ecuador and Peru: a qualitative study.
    Lafaurie MM; Grossman D; Troncoso E; Billings DL; Chávez S
    Reprod Health Matters; 2005 Nov; 13(26):75-83. PubMed ID: 16291488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review of the Effectiveness, Safety, and Acceptability of Mifepristone and Misoprostol for Medical Abortion in Low- and Middle-Income Countries.
    Ferguson I; Scott H
    J Obstet Gynaecol Can; 2020 Dec; 42(12):1532-1542.e2. PubMed ID: 32912726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical induced abortion].
    Bettahar K; Pinton A; Boisramé T; Cavillon V; Wylomanski S; Nisand I; Hassoun D
    J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1490-1514. PubMed ID: 27818118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes and Women's Experiences before and after the Introduction of Mifepristone into Second-Trimester Medical Abortion Services in South Africa.
    Constant D; Harries J; Malaba T; Myer L; Patel M; Petro G; Grossman D
    PLoS One; 2016; 11(9):e0161843. PubMed ID: 27583448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions of misoprostol among providers and women seeking post-abortion care in Zimbabwe.
    Maternowska MC; Mashu A; Moyo P; Withers M; Chipato T
    Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):16-25. PubMed ID: 25702065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days.
    Schaff EA; Fielding SL; Eisinger SH; Stadalius LS; Fuller L
    Contraception; 2000 Jan; 61(1):41-6. PubMed ID: 10745068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
    Schaff EA; Eisinger SH; Stadalius LS; Franks P; Gore BZ; Poppema S
    Contraception; 1999 Jan; 59(1):1-6. PubMed ID: 10342079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Availability of medical abortion medicines in eight countries: a descriptive analysis of key findings and opportunities.
    Grossman A; Prata N; Williams N; Ganatra B; Lavelanet A; Läser L; Asmani C; Elamin H; Ouedraogo L; Rahman MM; Conneh-Duworko MJ; Tehoungue BZ; Chanza H; Phiri H; Bhattarai B; Dhakal NP; Ojo OA; Afolabi K; Kabuteni TJ; Hailu BG; Moses F; Dlamini-Nqeketo S; Zulu T; Rehnström Loi U
    Reprod Health; 2023 Apr; 20(Suppl 1):58. PubMed ID: 37041543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.